SCHEMBL24328497

SCHEMBL24328497

COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(C(F)(F)F)c(Nc2cccc3c2N(S(C)(=O)=O)CC3)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 14/20 0.63
▸ INSR P06213 9/20 0.63
▸ IGF1R P08069 9/20 0.63
▸ EGFR P00533 6/20 0.62
▸ PLK1 P53350 2/20 0.61
▸ MET P08581 2/20 0.59
▸ BMPR1B O00238 1/20 0.58
▸ PLK4 O00444 1/20 0.58
▸ STK25 O00506 1/20 0.58
▸ RIOK3 O14730 1/20 0.58
▸ CHEK1 O14757 1/20 0.58
▸ CASK O14936 1/20 0.58
▸ AURKA O14965 1/20 0.58
▸ GAK O14976 1/20 0.58
▸ DCLK1 O15075 1/20 0.58
▸ MUSK O15146 1/20 0.58
▸ EPHB6 O15197 1/20 0.58
▸ PDPK1 O15530 1/20 0.58
▸ MAP3K13 O43283 1/20 0.58
▸ DAPK3 O43293 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30141606 1.00 ALK (0.63) ALKINSRIGF1REGFRPLK1
SCHEMBL24327359 0.91 ALK (0.69) ALKINSRIGF1REGFRPLK1
SCHEMBL26778364 0.90 ALK (0.77) ALKINSRIGF1REGFRPLK1
SCHEMBL26778373 0.90 ALK (0.69) ALKINSRIGF1REGFRPLK1
SCHEMBL29661359 0.90 ALK (0.65) ALKINSRIGF1REGFRPLK1
SCHEMBL26655418 0.90 ALK (0.65) ALKINSRIGF1REGFRPLK1
SCHEMBL24327332 0.88 ALK (0.67) ALKINSRIGF1REGFRPLK1
SCHEMBL29661302 0.88 ALK (0.63) ALKINSRIGF1REGFRPLK1
SCHEMBL24327443 0.88 ALK (0.63) ALKINSRIGF1REGFRPLK1
SCHEMBL27220773 0.88 ALK (0.63) ALKINSRIGF1REGFRPLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171416-A2 NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-05-29 — — US claimed
US-20240352000-A1 NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER KOREA RES INST CHEMICAL TECH (KR) 2024-10-24 — — US claimed
EP-4371983-A1 NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER Korea Research Institute of Chemical Technology (KR) 2024-05-22 — — EP claimed
US-20250171416-A2 NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-05-29 — — US disclosed
US-20240352000-A1 NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER KOREA RES INST CHEMICAL TECH (KR) 2024-10-24 — — US disclosed
EP-4371983-A1 NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER Korea Research Institute of Chemical Technology (KR) 2024-05-22 — — EP disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 — — US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 — — US disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 ALK 13/4885INSR 82/4885IGF1R 7/4885
US-20240352000-A1 NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER WEE2, WEE1, ERBB2 ALK 1560/4885INSR 2235/4885IGF1R 1053/4885
US-20250171416-A2 NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER WEE2, WEE1, ERBB2 ALK 1560/4885INSR 2235/4885IGF1R 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback